BPC-157 vs TB-500
Bottom line
BPC-157 and TB-500 are the two most popular “repair” peptides, frequently combined in the Wolverine Stack — but both rest almost entirely on animal and in-vitro data, with no large human trials for their popular soft-tissue uses. BPC-157 is a stable, acid-resistant 15-amino-acid peptide that can be dosed orally and is associated more with localized tissue and gut healing; TB-500 is a Thymosin Beta-4 fragment dosed weekly by injection and framed more around systemic cell migration and regeneration. Neither is FDA-approved, and TB-500 is banned in sport.
At a glance
| BPC-157 | TB-500 | |
|---|---|---|
| Class | Synthetic pentadecapeptide (gastric-juice–derived, BPC) | Thymosin Beta-4 fragment (Ac-LKKTETQ, Tβ4 17–23) |
| Primary use | Tendon/ligament/muscle repair; gut protection (claimed) | Soft-tissue repair, cell migration, regeneration (claimed) |
| Evidence level | Preclinical — mostly rodent, much from one research lineage | Preclinical — animal/in-vitro; parent protein reached Phase I/II |
| Typical weight loss / effect size | No quantified human effect size; healing claims are animal-derived/anecdotal | No quantified human effect size; healing claims are animal-derived/anecdotal |
| Half-life | Short (~minutes in animal data); human PK poorly characterized | Not well established in humans; parent protein ~hours, route-dependent |
| Route | Subcutaneous · Oral (acid-stable) · Intramuscular | Subcutaneous · Intramuscular (injection-only) |
| Legal / FDA status | Not FDA-approved; 503A Category 2, under compounding review (PCAC 2026) | Not FDA-approved; Tβ4 under 503A review; banned by WADA (S2) |
Key Differences
- What they are. BPC-157 is a 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV) derived from a protective protein in gastric juice, engineered to be stable in stomach acid. “TB-500” is usually the short Ac-LKKTETQ (Tβ4 17–23) fragment of Thymosin Beta-4 — not the full 43-amino-acid protein that was studied in clinical trials, a distinction often blurred in marketing.
- Proposed mechanism. BPC-157’s animal-model mechanisms center on angiogenesis (VEGFR2–Akt–eNOS), nitric-oxide modulation, and growth-factor/FAK–paxillin signaling, plus direct gut cytoprotection. TB-500 acts via actin sequestration/regulation, promoting cell migration and angiogenesis during repair. Neither has a clearly established human receptor target for the marketed forms.
- Dosing cadence and route. BPC-157 is dosed frequently (often 1–2× daily) because of its short half-life and can be taken orally (especially for gut goals). TB-500 is dosed weekly (a loading phase then maintenance) and is injection-only.
- Use-case framing. BPC-157 leans toward localized tendon/ligament and gastrointestinal applications; TB-500 is framed around systemic, whole-body cell migration and regeneration. These distinctions come largely from preclinical and anecdotal sources, not human RCTs.
- Human evidence. Both are preclinical. TB-500 has an indirect edge in that its parent protein (Tβ4) reached Phase I/II human trials (e.g. RGN-259 eye drops, RGN-352) with a favorable safety signal — but those trials do not validate the injectable bodybuilding fragment. BPC-157’s human data is minimal and much of the rodent work originates from a single research group.
- Regulatory and sport status. Neither is FDA-approved; both are flagged in the FDA’s 503A compounding review (PCAC 2026). Critically, TB-500 / Thymosin Beta-4 is explicitly banned by WADA (Prohibited List, S2, since 2012) — tested athletes risk sanctions. BPC-157’s sport status varies and should be assumed restricted.
- Shared risks. Both are sold as lyophilized research chemicals with unguaranteed identity/purity, both carry a theoretical pro-angiogenesis/tumor concern (not adequately studied in humans), and “well tolerated” reflects a lack of studies rather than proven safety. See Healing & Recovery, Joint & Tendon Repair.
Which Is Right For Whom
- This is a comparison of research-only peptides with no approved human use, so there is no medical “right choice” — only the recognition that human evidence is weak for both.
- In community practice, BPC-157 is often favored for localized soft-tissue or gut goals (and is the one discussed orally), while TB-500 is chosen for systemic recovery; the two are most often used together in the Wolverine Stack rather than as alternatives.
- Tested athletes should note that TB-500 is explicitly prohibited in sport; BPC-157 should also be treated as restricted.
- Anyone considering either should weigh the absence of large human trials, unverified sourcing, and unestablished long-term safety, and consult a qualified clinician. See Evidence Grading Explained and Regulatory & Legal Status.
Not medical advice — See Disclaimer.
References
- Chang C-H. et al. (2011). “The promoting effect of pentadecapeptide BPC 157 on tendon healing…” Journal of Applied Physiology.
- Gwyer D., Wragg N.M., Wilson S.L. (2019). “Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing.” Cell and Tissue Research.
- Goldstein A.L., Hannappel E., Kleinman H.K. (2005). “Thymosin β4: actin-sequestering protein moonlights to repair injured tissues.” Trends in Molecular Medicine.
- RegeneRx Biopharmaceuticals — Tβ4 clinical programs (RGN-259 dry eye; RGN-352 systemic), Phase I/II safety data.
- World Anti-Doping Agency (WADA). Prohibited List — thymosin beta-4 (S2), in force since 2012. U.S. FDA (2023–2026), bulk drug substances under 503A evaluation — BPC-157 and thymosin beta-4.
← Stacks · Home Educational information only — not medical advice. See Disclaimer.